Main > A1. CORP. INDEX. B-Bm > BeiGene./P C2
BeiGene./P C2's subsections
2011. 08.29. Chairman
2011. 08.29. CMO
2011. 08.29. CSO
2011. 10.14. Janssen Pharma
2013. 05.31. Merck KGaA>BRAF
2013. 11.13. Merck KGaA>PARP
2014. 11.14. Financing
2017. 03.07. Biologics MFG Facility
2019. 04.09. BioAtla
2019. 11.14. Lymphoma>MCL
2019. 12.27. Hodgkins Lymphoma
2020. 11.19. GCTB & SREs
2021. 01.13. Squamous NSCLC>CN>OK
2021. 06.23. Non-Squamous NSCLC>CN>
2021. 07.09. MM R/R
2021. 09.01. WM USA OK
2021. 09.15. Lymphoma>MZL
2021. 10.01. WM SG OK
2021. 10.07. WM AU OK
2022. 01.06. NSCLC
2022. 02.17. WM CH OK
2022. 03.03. MZL R/R CA>OK
2022. 03.11. Solid Tumors>MSI-H>CN>
2022. 03.15. WM IL OK
2022. 05.04. Onco.>ALL>CN>OK
2022. 06.10. Onco.>NPC>CN>OK
2022. 11.02. Onco.>MZL>EU>OK
2022. 11.10. Onco.>BR Approvals
2022. 11.17. Onco.>CLL>EU>OK
2023. 01.19. Onco.>CLL/MZL>UK>OK
2023. 02.24. Onco.>G/GEJ>CN>OK
2023. 05.30. Onco.>CLL>CA>OK
2023. 11.21. Ensem Therapeutics
2024. 03.14. Onco.>ESCC>USA>OK
2024. 04.23. Onco.,>NSCLC>EU>OK
Web-Site
BeiGene./P C2's products
This section has no products